AN FRANCISCO — The drug industry’s top lobbying group has a plan for the $100 million in extra dues it will soon be collecting from members: a stepped-up ad campaign highlighting just how hard it is to invent new treatments.

Pharmaceutical Research and Manufacturers of America, which just raised its annual fees by 50 percent, is hoping to counter the industry’s worsening reputation, brought on by increased public scrutiny of escalating drug prices. One facet of that effort will be a national ad campaign, PhRMA President and CEO Stephen Ubl said Monday at the J.P. Morgan Healthcare Conference.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.